Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Mibefradil (trade name Posicor) was a pharmaceutical drug used for the treatment of hypertension and chronic angina pectoris. It is a nonselective calcium channel blocker. It was voluntary pulled from the market ten months after FDA approval, citing potential serious health hazards shown in post release studies.
Overview, Related Topics & Entities
Explore the main themes, entities and connections around Mibefradil. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
market drug calcium voluntary fda approval potential trade name posicor synthesis hypertension t-type l-type roche pharmaceutical used treatment chronic angina
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Mibefradil | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Mibefradil | AHFS/Drugs.com | Micromedex Detailed Consumer Information | 1.00 | infobox |
| Mibefradil | ATC code | C08CX01 (WHO) | 1.00 | infobox |
| Mibefradil | Bioavailability | 70% | 1.00 | infobox |
| Mibefradil | CAS Number | 116644-53-2 Y | 1.00 | infobox |
| Mibefradil | ChEMBL | ChEMBL45816 N | 1.00 | infobox |
| Mibefradil | ChemSpider | 54673 N | 1.00 | infobox |
| Mibefradil | CompTox Dashboard (EPA) | DTXSID1023318 | 1.00 | infobox |
| Mibefradil | DrugBank | DB01388 N | 1.00 | infobox |
| Mibefradil | Elimination half-life | 17–25 hours | 1.00 | infobox |
| Mibefradil | Formula | C29H38FN3O3 | 1.00 | infobox |
| Mibefradil | IUPHAR/BPS | 2522 | 1.00 | infobox |
| Mibefradil | KEGG | D08217 Y | 1.00 | infobox |
| Mibefradil | Legal status | Withdrawn from market | 1.00 | infobox |
| Mibefradil | MedlinePlus | a607007 | 1.00 | infobox |
| Mibefradil | Melting point | 128 °C (262 °F) (dihydrochloride salt) | 1.00 | infobox |
| Mibefradil | Metabolism | Liver (CYP3A4) | 1.00 | infobox |
| Mibefradil | Molar mass | 495.639 g·mol−1 | 1.00 | infobox |
| Mibefradil | PDB ligand | MWV (PDBe, RCSB PDB) | 1.00 | infobox |
| Mibefradil | Protein binding | >99% | 1.00 | infobox |
| Mibefradil | PubChem CID | 60662 | 1.00 | infobox |
| Mibefradil | Routes of administration | By mouth (tablets) | 1.00 | infobox |
| Mibefradil | Trade names | Posicor | 1.00 | infobox |
| Mibefradil | UNII | 27B90X776A | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.